KR20160016756A - Adamts13의 피하 투여 - Google Patents

Adamts13의 피하 투여 Download PDF

Info

Publication number
KR20160016756A
KR20160016756A KR1020157028432A KR20157028432A KR20160016756A KR 20160016756 A KR20160016756 A KR 20160016756A KR 1020157028432 A KR1020157028432 A KR 1020157028432A KR 20157028432 A KR20157028432 A KR 20157028432A KR 20160016756 A KR20160016756 A KR 20160016756A
Authority
KR
South Korea
Prior art keywords
adamts13
mammal
administered
hours
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020157028432A
Other languages
English (en)
Korean (ko)
Inventor
알렉산드라 나탈리 쉬비츠
베르너 횔리에글
바바라 플라이마우어
한스페터 로텐스타이너
에바-마리아 무치쉬
Original Assignee
박스알타 인코퍼레이티드
박스앨타 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 박스알타 인코퍼레이티드, 박스앨타 게엠베하 filed Critical 박스알타 인코퍼레이티드
Publication of KR20160016756A publication Critical patent/KR20160016756A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020157028432A 2013-03-15 2014-03-13 Adamts13의 피하 투여 Ceased KR20160016756A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361794659P 2013-03-15 2013-03-15
US61/794,659 2013-03-15
PCT/US2014/026747 WO2014151968A1 (en) 2013-03-15 2014-03-13 Subcutaneous administration of adamts13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197005635A Division KR102102087B1 (ko) 2013-03-15 2014-03-13 Adamts13의 피하 투여

Publications (1)

Publication Number Publication Date
KR20160016756A true KR20160016756A (ko) 2016-02-15

Family

ID=50549463

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020157028432A Ceased KR20160016756A (ko) 2013-03-15 2014-03-13 Adamts13의 피하 투여
KR1020197005635A Active KR102102087B1 (ko) 2013-03-15 2014-03-13 Adamts13의 피하 투여
KR1020227005350A Active KR102513872B1 (ko) 2013-03-15 2014-03-13 Adamts13의 피하 투여
KR1020217004442A Active KR102365936B1 (ko) 2013-03-15 2014-03-13 Adamts13의 피하 투여
KR1020207010406A Active KR102218489B1 (ko) 2013-03-15 2014-03-13 Adamts13의 피하 투여

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020197005635A Active KR102102087B1 (ko) 2013-03-15 2014-03-13 Adamts13의 피하 투여
KR1020227005350A Active KR102513872B1 (ko) 2013-03-15 2014-03-13 Adamts13의 피하 투여
KR1020217004442A Active KR102365936B1 (ko) 2013-03-15 2014-03-13 Adamts13의 피하 투여
KR1020207010406A Active KR102218489B1 (ko) 2013-03-15 2014-03-13 Adamts13의 피하 투여

Country Status (18)

Country Link
US (4) US9611467B2 (enExample)
EP (2) EP3960196A1 (enExample)
JP (4) JP6484216B2 (enExample)
KR (5) KR20160016756A (enExample)
CN (2) CN114259558A (enExample)
AU (5) AU2013203062C1 (enExample)
BR (1) BR112015023542A8 (enExample)
CA (1) CA2905058A1 (enExample)
DK (1) DK2968483T3 (enExample)
EA (2) EA034546B1 (enExample)
ES (1) ES2906550T3 (enExample)
IL (3) IL241305B (enExample)
MX (2) MX380485B (enExample)
PL (1) PL2968483T3 (enExample)
PT (1) PT2968483T (enExample)
SG (3) SG11201507271QA (enExample)
TW (4) TWI740207B (enExample)
WO (1) WO2014151968A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022108148A1 (ko) * 2020-11-18 2022-05-27 주식회사 녹십자 자가 항체에 대한 회피율 또는 활성이 증가된 adamts13 변이체
WO2024151093A1 (ko) * 2023-01-11 2024-07-18 주식회사 녹십자 혈전성 질환의 예방 또는 치료를 위한 신규한 액상 제형물

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203062C1 (en) * 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13
GB201510870D0 (en) * 2015-05-26 2015-08-05 Baxalta Inc And Katholieke Universiteit Leuven And Baxalta Gmbh Treatment of infarction
MX2019001255A (es) 2016-08-04 2019-05-20 Baxalta Inc Uso de una desintegrina y metaloproteinasa con motivo tipo 1 de trombospondina, miembro-13 (adamts13) para tratar, mejorar y/o prevenir crisis vaso-oclusiva en enfermedad de celulas falciformes, lesion pulmonar aguda y/o sindrome de insuficiencia respiratoria aguda.
WO2020214033A1 (en) * 2019-04-17 2020-10-22 Erasmus University Medical Center Rotterdam Papain-like cysteine peptidase medicaments and uses thereof
US20220339266A1 (en) 2019-10-04 2022-10-27 The Children's Medical Center Corporation Adamts13 treatment to enhance graft survival
AU2021248679A1 (en) 2020-04-02 2022-10-27 Takeda Pharmaceutical Company Limited ADAMTS13 variant, compositions, and uses thereof
CN115835904A (zh) * 2020-05-22 2023-03-21 武田药品工业有限公司 用于治疗和诊断冠状病毒疾病并发症的adamts13组合物和方法
EP4158012A1 (en) * 2020-05-25 2023-04-05 Sanquin IP B.V. Adamts13 protein variants and uses thereof
GB202102208D0 (en) * 2021-02-17 2021-03-31 Univ Manchester Adamts13 variant

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113010A (en) 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US6926894B2 (en) 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
WO2003016492A2 (en) * 2001-08-16 2003-02-27 The Regents Of The University Of Michigan Adamts13 genes and proteins and variants, and uses thereof
US7763430B2 (en) 2003-04-22 2010-07-27 Baxter International Inc. Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies
AU2006257073B2 (en) * 2005-06-17 2011-08-04 Children's Medical Center Corporation ADAMTS13-comprising compositions having thrombolytic activity
JP2009539757A (ja) * 2006-06-16 2009-11-19 バクスター・インターナショナル・インコーポレイテッド 血栓溶解活性を有するａｄａｍｔｓ１３含有組成物
US20090317375A1 (en) * 2008-05-12 2009-12-24 Immune Disease Institute, Inc. Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
CA2770609A1 (en) * 2009-08-20 2011-02-24 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
FI3834841T3 (fi) * 2009-09-21 2023-06-05 Takeda Pharmaceuticals Co Stabiloituja neste- ja lyofilisoituja ADAMTS13-formulaatioita
EP2591094B1 (en) * 2010-07-08 2018-09-05 Baxalta GmbH Method of producing recombinant adamts13 in cell culture
AU2013203062C1 (en) * 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022108148A1 (ko) * 2020-11-18 2022-05-27 주식회사 녹십자 자가 항체에 대한 회피율 또는 활성이 증가된 adamts13 변이체
KR20250021517A (ko) * 2020-11-18 2025-02-13 주식회사 녹십자 자가 항체에 대한 회피율 또는 활성이 증가된 adamts13 변이체
WO2024151093A1 (ko) * 2023-01-11 2024-07-18 주식회사 녹십자 혈전성 질환의 예방 또는 치료를 위한 신규한 액상 제형물

Also Published As

Publication number Publication date
TWI690326B (zh) 2020-04-11
MX2015012783A (es) 2016-04-28
KR102102087B1 (ko) 2020-04-20
IL241305A0 (en) 2015-11-30
ES2906550T3 (es) 2022-04-19
KR20220027266A (ko) 2022-03-07
US20200101144A1 (en) 2020-04-02
BR112015023542A2 (pt) 2017-07-18
NZ749570A (en) 2020-11-27
JP2023071821A (ja) 2023-05-23
US11779635B2 (en) 2023-10-10
AU2016231547B2 (en) 2018-03-15
EA201591758A8 (ru) 2017-03-31
PT2968483T (pt) 2022-02-23
IL290486A (en) 2022-04-01
IL241305B (en) 2020-04-30
AU2016231547A1 (en) 2016-10-06
US9611467B2 (en) 2017-04-04
SG10202001227QA (en) 2020-03-30
AU2018203665B2 (en) 2020-01-30
CN114259558A (zh) 2022-04-01
JP7238088B2 (ja) 2023-03-13
KR20190022926A (ko) 2019-03-06
AU2013203062A1 (en) 2014-10-02
US20170224785A1 (en) 2017-08-10
KR102513872B1 (ko) 2023-03-27
IL290486B2 (en) 2023-08-01
EP2968483B1 (en) 2021-12-01
IL273365A (en) 2020-05-31
AU2013203062C1 (en) 2018-06-28
WO2014151968A8 (en) 2015-10-15
US20140271611A1 (en) 2014-09-18
AU2013203062B2 (en) 2016-06-23
SG11201507271QA (en) 2015-10-29
IL290486B1 (en) 2023-04-01
NZ751610A (en) 2020-11-27
EP3960196A1 (en) 2022-03-02
NZ712440A (en) 2020-11-27
TW202313664A (zh) 2023-04-01
TWI740207B (zh) 2021-09-21
SG10201707074TA (en) 2017-10-30
US10413600B2 (en) 2019-09-17
WO2014151968A1 (en) 2014-09-25
IL273365B (en) 2022-05-01
AU2022211908A1 (en) 2022-09-01
JP2016517421A (ja) 2016-06-16
KR20200041394A (ko) 2020-04-21
EA201591758A1 (ru) 2016-03-31
CA2905058A1 (en) 2014-09-25
JP2022027991A (ja) 2022-02-14
HK1220131A1 (zh) 2017-04-28
BR112015023542A8 (pt) 2019-12-03
DK2968483T3 (da) 2022-02-14
TWI786563B (zh) 2022-12-11
JP6484216B2 (ja) 2019-03-13
TW201513881A (zh) 2015-04-16
US20220080032A1 (en) 2022-03-17
AU2020202738B2 (en) 2022-06-09
EA034546B1 (ru) 2020-02-19
KR102365936B1 (ko) 2022-02-23
MX2021002513A (es) 2021-04-28
MX380485B (es) 2025-03-12
TW202017591A (zh) 2020-05-16
PL2968483T3 (pl) 2022-04-04
US11185575B2 (en) 2021-11-30
JP6998333B2 (ja) 2022-02-10
KR20210021107A (ko) 2021-02-24
AU2018203665A1 (en) 2018-06-14
JP2019142850A (ja) 2019-08-29
EP2968483A1 (en) 2016-01-20
TW202138003A (zh) 2021-10-16
AU2020202738A1 (en) 2020-05-14
AU2022211908B2 (en) 2023-11-30
CN105407912A (zh) 2016-03-16
EA201992832A1 (ru) 2020-05-31
KR102218489B1 (ko) 2021-02-22

Similar Documents

Publication Publication Date Title
JP7238088B2 (ja) Ａｄａｍｔｓ１３の皮下投与
HK40069281A (en) Subcutaneous administration of adamts13
EA045023B1 (ru) Подкожное введение adamts13
NZ751610B2 (en) Subcutaneous administration of adamts13
HK1220131B (en) Subcutaneous administration of adamts13
NZ712440B2 (en) Subcutaneous administration of adamts13

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20151012

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170303

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180314

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180903

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180314

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20180903

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20170303

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20181224

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20181203

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20180903

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20180314

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170303

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190225